Press releases

Media contact: Stéphanie Bardon – communication@genethon.fr – 01.69.47.12.78

Genethon Pursues Different Strategies for Ensuring Patient Access to Gene Therapies for Rare Diseases

(read more)

Spark Therapeutics Enters into Licensing Agreement with Genethon

(read more)

Audentes Therapeutics announces dosing of first patient in ASPIRO for the treatment of X-Linked Myotubular Myopathy

(read more)

Clinical results of the gene therapy trial in myotubular myopathy : efficacy on respiratory and motor functions in this extremely severe disease, challenges ahead

(read more)

The Latest Research of 14 Généthon Scientists to be Featured at the European Society of Gene & Cell Therapy’s 30th Annual Congress, Oct. 24-27, 2023, in Brussels, Belgium

(read more)

First results of Crigler-Najjar clinical trial published in New England Journal of Medicine

(read more)

Genethon and Thales collaborate on artificial intelligence to improve bioproduction efficiency

(read more)

Upholder of excellence in gene therapyGenother awarded Biocluster label

(read more)

Genethon’s R&D to be Featured in Multiple Presentations at American Society of Gene & Cell Therapy Annual Meeting May 16-20, 2023, in Los Angeles, CA

(read more)

ILTOO Pharma and the MIROCALS Consortium announce the signing of Licence Agreement for the development of low dose interleukin-2 as a potential treatment for Amyotrophic Lateral Sclerosis (ALS)

(read more)

Crigler-Najjar syndrome: Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy for patients with anti-AAV antibodies

(read more)

Crigler-Najjar Syndrome: Genethon obtains PRIME priority drug status from the EMA for its gene therapy

(read more)

Genethon Launches Pivotal Clinical Trial of Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease

(read more)

Genethon’s Latest Research, Including Advances in Gene Editing and AAV Delivery Vectors for Gene Therapy, to be Featured at European Society for Gene and Cell Therapy, Oct. 11-14, 2022

The gene therapy pioneering organization’s scientists will make multiple presentations on research aimed at curing rare diseases.

(read more)

First Patient Dosed in Phase 1/2 Clinical Trial in Europe of Gene Therapy for LGMD-R9

Study to treat FKRP-related limb-girdle muscular dystrophy type 2I/R9 represents 30 years of research and is being conducted by Genethon spinout Atamyo Therapeutics.

(read more)